News

Estrogen patch shortage intensifies after FDA endorsement drives demand beyond manufacturing capacity, leaving patients searching for alternatives.

Atlanta clinic receives top recognition for GLP-1 and peptide therapy services as demand for metabolic treatments grows nationwide.

Duluth medical facility receives top recognition for GLP-1 and peptide therapy programs as demand for metabolic treatments grows.

Genetic variations may explain why some patients respond dramatically to GLP-1 drugs while others see minimal weight loss results.

FDA seizes thousands of counterfeit Ozempic units found in legitimate U.S. pharmacies and warns consumers to verify product authenticity.

Estrogen patch shortages affect women seeking hormone therapy as demand surges and supply chain struggles to keep pace.

The peptide craze reveals Americans’ willingness to embrace unproven treatments despite limited safety data and regulatory oversight.

UK medicines watchdog MHRA investigates peptide clinics over concerns about unsubstantiated health claims and marketing practices.

Novo Nordisk expands its obesity treatment lineup with a high-dose Wegovy formulation as competition in the GLP-1 market intensifies.

Indirect comparison reveals oral semaglutide produces greater weight loss than orforglipron in clinical trial analysis.